KR20210084481A - 수면 무호흡증의 치료 방법 및 조성물 - Google Patents

수면 무호흡증의 치료 방법 및 조성물 Download PDF

Info

Publication number
KR20210084481A
KR20210084481A KR1020217013074A KR20217013074A KR20210084481A KR 20210084481 A KR20210084481 A KR 20210084481A KR 1020217013074 A KR1020217013074 A KR 1020217013074A KR 20217013074 A KR20217013074 A KR 20217013074A KR 20210084481 A KR20210084481 A KR 20210084481A
Authority
KR
South Korea
Prior art keywords
oxybutynin
composition
hydroxyatomoxetine
subject
muscarinic receptor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020217013074A
Other languages
English (en)
Korean (ko)
Inventor
로렌스 쥐. 밀러
로날드 파르카스
Original Assignee
애프니메드, 인코포레이티드 (델라웨어)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 애프니메드, 인코포레이티드 (델라웨어) filed Critical 애프니메드, 인코포레이티드 (델라웨어)
Publication of KR20210084481A publication Critical patent/KR20210084481A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020217013074A 2018-10-31 2019-07-23 수면 무호흡증의 치료 방법 및 조성물 Ceased KR20210084481A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862753420P 2018-10-31 2018-10-31
US62/753,420 2018-10-31
PCT/US2019/043065 WO2020091862A1 (en) 2018-10-31 2019-07-23 Methods and compositions for treating sleep apnea

Publications (1)

Publication Number Publication Date
KR20210084481A true KR20210084481A (ko) 2021-07-07

Family

ID=67539629

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020217013074A Ceased KR20210084481A (ko) 2018-10-31 2019-07-23 수면 무호흡증의 치료 방법 및 조성물

Country Status (9)

Country Link
US (3) US20210401790A1 (https=)
EP (1) EP3873454A1 (https=)
JP (2) JP2022506113A (https=)
KR (1) KR20210084481A (https=)
CN (1) CN112930179A (https=)
AU (1) AU2019370091A1 (https=)
CA (1) CA3117766A1 (https=)
MX (2) MX2021004883A (https=)
WO (1) WO2020091862A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20240021920A (ko) * 2021-06-17 2024-02-19 애프니메드, 인코포레이티드 (델라웨어) 수면 무호흡증을 치료하기 위한 노르에피네프린 재흡수 억제제
MX2024007764A (es) * 2021-12-22 2024-07-04 Bayer Ag Combinacion de un bloqueante de canales task1/3 con un inhibidor de la recaptacion de norepinefrina para el tratamiento de la apnea del sue?o.
US20250049779A1 (en) * 2021-12-22 2025-02-13 Bayer Aktiengesellschaft Combination of an a2-adrenoceptor subtype c (alpha-2c) antagonist with a norepinephrine reuptake inhibitor for the treatment of sleep apnea
CN119789855A (zh) * 2022-09-02 2025-04-08 爱普宁公司(特拉华) 治疗睡眠呼吸暂停的方法和组合物

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US7160898B2 (en) * 2001-12-14 2007-01-09 Board Of Trustees Of The University Of Illinois Pharmacological treatment for sleep apnea
PT1257277E (pt) * 2000-02-24 2005-09-30 Pharmacia & Upjohn Co Llc Novas combinacoes de farmacos
CH695982A5 (de) * 2001-03-06 2006-11-15 Lilly Co Eli Inhibitor der Monaminaufnahme.
US20050176680A1 (en) * 2003-12-11 2005-08-11 Sepracor, Inc. Combination of sedative and a neurotransmitter modulator, and methods for improving sleep quality and treating depression
US20080145318A1 (en) * 2006-12-13 2008-06-19 Midha Kamal K Atomoxetine formulations and associated methods
JP2012176958A (ja) * 2012-04-20 2012-09-13 Watson Pharmaceuticals Inc （ｒ）−オキシブチニンおよび（ｒ）−デスエチルオキシブチニンによる平滑筋機能亢進の処置
CN106714790A (zh) * 2014-07-22 2017-05-24 托马斯·P·杜利 使用β肾上腺素能受体拮抗剂和毒蕈碱受体拮抗剂组合的治疗惊恐和焦虑症状的药物组合物和方法
AU2018260666B2 (en) * 2017-04-28 2022-07-21 The Brigham And Women's Hospital, Inc. Methods and compositions for treating sleep apnea

Also Published As

Publication number Publication date
MX2024013184A (es) 2024-12-06
JP2022506113A (ja) 2022-01-17
CA3117766A1 (en) 2020-05-07
EP3873454A1 (en) 2021-09-08
US20210401790A1 (en) 2021-12-30
WO2020091862A1 (en) 2020-05-07
MX2021004883A (es) 2021-08-05
JP2024088740A (ja) 2024-07-02
US20250325510A1 (en) 2025-10-23
CN112930179A (zh) 2021-06-08
US20250114321A1 (en) 2025-04-10
AU2019370091A1 (en) 2021-05-27

Similar Documents

Publication Publication Date Title
US20250186371A1 (en) Methods and compositions for treating sleep apnea
US20240261239A1 (en) Methods and compositions for treating sleep apnea
US20250114321A1 (en) Methods and compositions for treating sleep apnea
HK40117857A (en) Methods and compositions for treating sleep apnea
EA047115B1 (ru) Способы и композиции для лечения апноэ сна
HK40031779B (en) Methods and compositions for treating sleep apnea or simple snoring
HK40031779A (en) Methods and compositions for treating sleep apnea or simple snoring

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20210429

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20220715

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20241031

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20250507

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D